Our Current Trials

Condition	Trial Name	Sponsor
Solid Tumors	1403-0002: MDM2 Inhibitor BI 907828 and Anti PD-1 Antibody Ezabenlimab in Select Solid Tumors	Boehringer Ingelheim
Solid Tumors	1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors	Mirati Therapeutics, Inc.
Rectal Cancer	19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma	Memorial Sloan Kettering Cancer Center
Breast Cancer	ASCENT-03: Sacituzumab Govitecan as First Line Treatment for Patients With Triple Negative Breast Cancer	Gilead Sciences
Breast Cancer	ASCENT-04: Sacituzumab Govitecan in Combination With Pembrolizumab as First Line Treatment for Patients With PD-L1 Expressing Triple Negative Breast Cancer	Gilead Sciences
Breast Cancer	ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer	Gilead Sciences, Inc.
Cachexia in Colorectal or Pancreatic Cancer	AV-380-22-102: Study of GDF-15 Inhibitor AV-380 for the Treatment of Cachexia in Patients with Metastatic Colorectal or Pancreatic Cancer Receiving First Line Chemotherapy	AVEO Pharmaceuticals, Inc.
Solid Tumors	BI 1403-0001: MDM2 inhibitor BI 907828 in MDM2 Amplified Advanced Solid Tumors	Boehringer Ingelheim
Breast Cancer	BRIA-ABC: Bria-IMT plus Immunotherapy for Patients with Pre-Treated Metastatic Breast Cancer	BriaCell Therapeutics Corporation
Solid Tumor or Lymphoma	CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas	CStone Pharmaceuticals
Breast Cancer	ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor	Stemline Therapeutics, Inc.
Central Nervous System Cancer	F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy	Fore Biotherapeutics
Solid Tumors	F8394-201a: BRAF Inhibitor FORE8394 for the Treatment of BRAF Fusion Positive Advanced Solid Tumors	Fore Biotherapeutics
Gastric or Gastroesophageal Junction Cancer	GEMINI-C: First Line Treatment for Patients with an Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	AstraZeneca
Head and Neck Squamous Cell Carcinoma	GS-US-548-5916: Magrolimab Combinations in Recurrent or Metastatic HNSCC	Gilead Sciences, Inc.
Non-Small Cell Lung Cancer	HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma	Lantern Pharma Inc.
Colon or Rectal Cancer	INTRINSIC: A Multi-Arm Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer	Hoffmann-La Roche
Non-Small Cell Lung Cancer	KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation	Mirati Therapeutics, Inc.
Solid Tumors	KRYSTAL-1: Multiple Cohort Study of Adagrasib Monotherapy or Combinations for Patients With KRAS G12C Mutant Solid Tumors	Mirati Therapeutics Inc.
Colon or Rectal Cancer	LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash	Lutris Pharma Ltd.
Non-Hodgkin Lymphoma	MorningSun: Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies	Genentech, Inc.
Hyperkalemia/Chronic Kidney Disease	NYH-01: Hyperkalemia/Chronic Kidney Disease	Relypsa
Breast Cancer	OPERA-01: OP-1250 (palazestrant) in ER-Positive and HER2-Negative Metastatic Breast Cancer Previously Treated with a CDK4/6 Inhibitor	Olema Pharmaceuticals, Inc.
Solid Tumors	PRECISION 1: Nab-Sirolimus for the Treatment of Patients With TSC1/2 Mutant Advanced or Metastatic Solid Tumor	Aadi Bioscience, Inc.
ITP, wAIHA, CAD	RUBY-4: Povetacicept (ALPN-303) for Patients with Autoimmune Cytopenias	Alpine Immune Sciences, Inc.
Breast Cancer	SERENA-6: AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression	AstraZeneca
Breast Cancer	SPI-GCF-104: Same Day Administration of Eflapegrastim to Treat Neutropenia in Patients Being Treated With Neo/Adjuvant Docetaxel Plus Cyclophosphamide	Spectrum Pharmaceuticals, Inc.
Solid Tumors	TAPISTRY: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You Platform Study	Hoffmann-La Roche
Non-Small Cell Lung Cancer	TROPION-Lung07: Datopotamab Deruxtecan Combinations vs Standard Chemo/Immunotherapy for the First Line Treatment of Non-Squamous Non-Small Cell Lung Cancer	Daiichi Sankyo, Inc.
Ovarian, Fallopian Tube or Primary Peritoneal Cancer	ZN-c3-005: Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer	K-Group, Beta, Inc.
Cancer Diagnosis	[Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients	Memorial Sloan Kettering Cancer Center
Various Indications	[Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx)	Precision for Medicine
Solid Tumors	[Sample Collection] Collection and Distribution of Biofluids for Research Purposes	Bluestar Genomics
Solid Tumors	[Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2)	Exact Sciences Thrive LLC
Various Indications	[Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022)	MT Group
Various Indications	[Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035)	SERATRIALS, LLC.
Solid Tumors	[Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening	Freenome Holdings Inc.
Solid Tumors	eNRGy: HER2xHER3 Bispecific Antibody MCLA-128 for the Treatment of an Advanced or Metastatic Solid Tumor Malignancy With a Documented NRG1 Fusion	Merus N.V.

Our Current Trials

Call Us